iarjcrIARJCRIARJCR2789-6064https://doi.org/10.47310/iarjcr.2023.v03i01.004Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires the exclusion of all differential diseasesJosefFinstererFulvioA. ScorzaNeurology and Neurophysiology Center, Vienna, AustriaDisciplina de Neurociência. Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM). São Paulo, BrasilIt is well appreciated that Guillain-Barre syndrome (GBS) can be a peripheral nervous system (PNS) complication of COVID-19. All subtype of GBS have been reported in association with SARS-CoV-2 infections. SARS-CoV-2 associated GBS should be diagnosed according to the Brighton criteria where one condition is the dissociation cyto-albuminique. If patients diagnosed with GBS have pleocytosis and additionally develop impaired consciousness, alternative diagnoses should be adequately ruled out. One of these differential diagnoses is infectious or immune encephalitis. Cerebral imaging with contrast medium and extensive cerebrospinal fluid (CSF) examinations are required to rule out or confirm encephalitis. Before diagnosing SARS-CoV-2 related GBS, all differential diagnoses need to adequately rule out.